AngioDynamics Q4 sales beat estimates on Med Tech strength

AngioDynamics

14/07/2026 11:11

Overview
US medical technology firm's fiscal Q4 sales rose 8%, beating analyst expectations
Adjusted EPS and adjusted net income for Q4 beat analyst estimates, but both remained negative
Quarterly growth driven by Med Tech segment, with strong NanoKnife and Auryon sales

Outlook
AngioDynamics sees fiscal 2027 net sales between $336 mln and $341 mln
Company expects Med Tech net sales growth of 12%–15% and Med Device net sales growth flat
AngioDynamics expects gross margin of 54%–55% and adjusted EBITDA of $13 mln–$16 mln for fiscal 2027

Result Drivers
NANOKNIFE GROWTH - NanoKnife sales rose 64.5% in Q4, driven by 47% growth in probes and 132.5% growth in capital sales, supported by new reimbursement milestones and positive clinical data
AURYON PLATFORM - Auryon sales increased 14.4% year-over-year, contributing to Med Tech segment growth
GROSS MARGIN IMPROVEMENT - Gross margin rose 130 basis points to 54.0%, mainly due to favorable pricing and a shift toward higher-margin Med Tech products

Company press release: ID:nBwLkbVSa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$86.60 mln
$80.40 mln (3 Analysts)
Q4 Adjusted EPS
Beat
-$0.07
-$0.09 (3 Analysts)
Q4 Adjusted Net Income
Beat
-$2.80 mln
-$3.82 mln (3 Analysts)
Q4 Net Income
 
-$11.40 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AngioDynamics Inc is $16.00, about 25.2% above its July 13 closing price of $12.78

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)